Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex's growth momentum remains strong, supported by ECC to S/4HANA migration and multi-year ERP upgrade cycle. Read my ...

Recent developments at Vertex include the initiation of Phase 3 trials for VX-522 for cystic fibrosis and VX-880 for type 1 diabetes, with promising initial data from the Povetacicept program for ...

Analyst William Pickering of Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX ... implications for the ongoing DPN Phase 3 trial. However, the current market sentiment ...

Gena Wang, an analyst from Barclays, maintained the Hold rating on Vertex Pharmaceuticals (VRTX ... The initiation of a Phase 3 trial for IgAN indicates progress, but the evaluation of ...

Revenue Growth: Vertex's revenue growth over a period of 3 months has been noteworthy ... or beneficial owner holding more than ten percent of a company's equity securities under Section 12 ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Vertex Pharmaceuticals (VRTX ... the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.

The continued support comes after Vertex presented more detailed Phase 3 information on its non-opioid pain medication, Suzetrigine, at the Anesthesiology Meeting. The new data provided insights into ...

Recent developments at Vertex include the initiation of Phase 3 trials for VX-522 for cystic fibrosis and VX-880 for type 1 diabetes, with promising initial data from the Povetacicept program for IgA ...